Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lyophilized haemophilus influenzae type b conjugate vaccine
- Development stage
- Unknown
- Lead developer
- CanSino Biologics
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
This is a lyophilized (freeze-dried) Haemophilus influenzae type b (Hib) conjugate vaccine being developed by CanSino Biologics. The vaccine is a biologic designed to prevent invasive diseases caused by *Haemophilus influenzae* type b bacteria, such as meningitis and pneumonia. As a conjugate vaccine, it works by chemically linking the bacterial polysaccharide capsule to a carrier protein, which enhances the immune response, particularly in infants and young children whose immune systems do not respond effectively to plain polysaccharide vaccines. The vaccine is currently in Phase I clinical trials to evaluate its safety and immunogenicity in healthy participants aged 2 months to 59 years. CanSino is also developing this Hib component as part of a broader pentavalent combination vaccine (DTcP-Hib-MCV4).
- Other names
- Lyophilized Hib conjugate vaccineCanSino Hib vaccineHaemophilus influenzae type b conjugate vaccine
Beyond the preview
Go deeper on lyophilized haemophilus influenzae type b conjugate vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lyophilized haemophilus influenzae type b conjugate vaccine.